PHIBRO ANIMAL HEALTH CORP

For the period ended Mar 31, 2026. Filed May 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 6, 2026

PAHC$34.64+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Cash Flows


· · Nine Months ·
For the Periods Ended March 31 · · 2026 · · 2025 ·
· · (unaudited) ·
· · (in thousands) ·
OPERATING ACTIVITIES · · · · ·
Net income	$78,010	$31,040
Adjustments to reconcile net income to
net cash provided by operating activities:
Depreciation and amortization	38,169	33,194
Amortization of debt issuance costs	1,716	1,443
Deferred income taxes	9,668	(13,241)
Foreign currency losses, net	851	5,683
Acquisition-related items	1,956	3,342
Non-cash impairment charges	—	5,328
Stock-based compensation expense	1,184	538
Other	(1,359)	(1,167)
Changes in operating assets and liabilities, net of business acquisition
Accounts receivable, net	8,923	(29,251)
Inventories, net	(92,541)	(38,133)
Other current assets	6,656	(7,712)
Other assets	745	3,809
Accounts payable	(6,816)	42,936
Accrued expenses and other liabilities	(2,302)	21,043
Net cash provided by operating activities	44,860	58,852
INVESTING ACTIVITIES
Purchases of short-term investments	(37,026)	(10,000)
Maturities of short-term investments	23,504	44,000
Capital expenditures	(40,219)	(25,151)
Business acquisition, net of cash acquired	—	(291,878)
Other, net	(1,263)	1,375
Net cash used by investing activities	(55,004)	(281,654)
FINANCING ACTIVITIES
Revolving credit facility borrowings	221,000	479,000
Revolving credit facility repayments	(193,000)	(563,000)
Proceeds from long-term debt	—	650,000
Payments of long-term debt	(12,188)	(320,953)
Debt issuance costs	—	(10,377)
Payments of insurance premium financing and other short-term debt	(6,161)	(5,185)
Dividends paid	(14,596)	(14,585)
Net cash (used) provided by financing activities	(4,945)	214,900
Effect of exchange rate changes on cash	1,979	(2,357)
Net decrease in cash and cash equivalents	(13,110)	(10,259)
Cash and cash equivalents at beginning of period	68,039	70,613
Cash and cash equivalents at end of period	$54,929	$60,354

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.